Early Access Programs: What They Are And How To Plan For Them

Cencora - PharmaLex Talks 28

Early access programs are crafted to grant patients grappling with life-threatening unmet medical needs or diseases access to promising treatments that haven't yet garnered marketing approval. These programs encompass named patient initiatives tailored to individual sufferers of rare, ultra-rare, or life-threatening conditions, as well as cohort programs, which target groups of patients afflicted with the same disease.

About The Speaker: Patrick Larcier is Senior Director at PharmaLex, where he draws on his 30 years of experience in drug development and regulatory affairs at biotechnology companies, CROs, and in consulting. Patrick works on Strategic Product Development Solutions for PharmaLex’s global projects. His expertise lies in the design and implementation of regulatory strategies for complex and innovative medicinal products at all stages of clinical development.

access the Podcast!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.

Subscribe to Clinical Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Clinical Leader